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Objectives: Serum autoantibodies are pivotal for the early detection of systemic autoimmune rheumatic diseases
such as Systemic Sclerosis (SSc) and Poly/Dermatomyositis (PM/DM), and in some cases are associated with
organ complications such as interstitial lung disease (ILD). A paradigmatic example is provided by the autoan-
tibody against the Eukaryotic Initiation Factor 2B (eIF2B) that has been recently detected in SSc.
Methods: Sera from 118 patients with SSc, 8 Poly/Dermatomyositis, 2 overlap SSc/Polymyositis, 4 undifferenti-
ated connective tissue disease-UCTD and 3 healthy controls were tested first by indirect immunofluorescence for
anti-nuclear antibodies-ANA pattern. Further, we employed prot
ein-radioimmunoprecipitation (IP) and IP- Western Blot for the detection and confirmation of anti-eIF2B anti-
bodies. Serum findings were further correlated with the clinical features of patients.
Results: We identified 3 SSc cases (2.5%) positive for anti-eIF2B antibodies while this autoantibody was not
detected in control sera. Using protein-IP all three patients manifested the 38kD protein which is the antigenic
target of anti-eIF2B antibodies, and this was associated with a cytoplasmic pattern at indirect immunofluores-
cence. The presence of anti-eIF2B was associated with ILD and a diffuse SSc variant, in one case in association
with anti-Scl70/topoI.
Conclusions: Our data confirm that a small subgroup (2.5%) of patients with SSc have detectable anti-eIF2B with
cytoplasmic-positive staining at immunofluorescence and this reactivity is associated with ILD.1. Introduction
Serum autoantibodies (autoAbs) are fundamental for the diagnosis
and management of Systemic Sclerosis (SSc) and Poly/Dermatomyositis
(PM/DM) [2,3], with rare ones often associated with specific clinical
subsets [1] while more prevalent ones, such as anti-nuclear antibody
(ANA), have a high sensitivity being found in nearly 100% of patients
with connective tissue diseases. The prevalence of autoAbs in SSc and
PM/DM is influenced by gender and ethnicity [4] [2,3,5] and therefore
rare specificities need to be confirmed in different cohorts worldwide for
clinical and prognostic associations [6,7]. In the last decades several new
autoAbs have been discovered [6,8] with some becoming criteria for they and Clinical Immunology, Hum
mi).
evier B.V. This is an open access aclassification of patients [9], such as anti-RNA polymerase III (RNApolIII)
antibodies in SSc [10] and anti-Jo-1 in PM [11]. The presence of
anti-Eukaryotic Initiation Factor 2B (eIF2B) in SSc was described in 2016
in 1–2% of patients with diffuse cutaneous disease and interstitial lung
disease (ILD) and with negative ANA at indirect immunofluorescence
(IIF) [12] and these observations were confirmed in a British study in
2018 [13].
We will herein discuss the main autoAbs associated with the risk of
developing ILD in patients affected by SSc and PM/DM and report our
original data on the prevalence and clinical significance of anti-eIF2B in
SSc.anitas Research Hospital, via A. Manzoni 56, 20089, Rozzano, Milan, Italy.
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Table 1
Main clinical and laboratory features of the 3 patients with SSc with positive anti-
eIF2B antibodies.
Patient #1 Patient #2 Patient #3
Sex F F M
Age at present, years 65 75 88 (death from
myocardial
infarction)
Ethnic group Caucasian Caucasian Caucasian
SSc variant Diffuse Limited Diffuse
Interstitial lung disease þ þ þ
Gastrointestinal disease þ – –




Digital ulcers – þ þ
Skin calcinosis – – –
Raynaud’s phenomenon þ þ þ
Overlap Myositis – –
Cancer – – þ (Lung)











Fig. 1. Identification of anti-eIF2B in SSc shows (Panel A) IIF with a cytoplasmic stain
of the 38kD band which corresponds to the antigenic target of anti-eIF2B antibodies
antigenic target, as represented by the positive control (POS CTRL) and the 3 anti-e
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2. The case of anti-eIF2B in SSc
2.1. Subjects
We enrolled 118 consecutive patients affected by SSc, 2 PM/DM, 2
overlap SSc/PM, 4 undifferentiated connective tissue diseases (UCTD)
and 3 healthy controls (HC) and sera collected in the years 2013–2017
were tested for anti-eIF2B antibodies. All patients with SSc fulfilled
classification criteria [9] and the diffuse and limited variants were
defined based on LeRoy criteria [14]; clinical and laboratory character-
istics were derived from the medical records. ILD was determined by
pulmonary high-resolution computed tomography (HRCT) in the pres-
ence of a ground-glass reticular pattern and honeycombing extent [15].
Serum samples were obtained from all patients and stored at80 C until
used and at the same time clinical and laboratory data were collected.
The study was approved by the Institutional Review Board of the hos-
pital. This study met and was in compliance with the ethical standards of
medicine, and informed consent was obtained from all patients in
accordance with the Declaration of Helsinki and subsequent
modifications.2.2. Autoantibody detection
For autoAbs detection we used: (i) IIF using HEp-2 slides (INOVA, Saning in the 3 anti-eIF2B positive SSc cases, (Panel B) Protein-IP with the presence
, with variable intensity, and (Panel C) IP-WB confirming the presence of eIF2B
IF2B positive SSc sera.
Table 2









9.4–42 dSSc ILD, renal crisis, digital ulcers
Anti-
U3RNP





3 dSSc/lSSc ILD, PH
Anti-Th/To 2–5 lSSc ILD, PH, myositis





Anti-BICD2 – lSSc ILD and myositis
Anti-Ku 1.5–5 lSSc ILD, myositis and arthritis
Anti-
NOR90
4.8 lSSc ILD, arthritis, sicca
Abbreviations: dSSc, diffuse SSc; ILD, interstitial lung disease; lSSc, limited SSc;
PH, pulmonary hypertension.
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anti-human IgG AlexaFluor488 AffiniPure F (ab’)2 fragment (Jackson
Immunoresearch Europe Ltd, Suffolk, UK) and DAPI for nuclear staining;
(ii) protein-immunoprecipitation (IP) as previously described [8] to
identify the 38 kDa band which is the target antigen for anti-eIF2B an-
tibodies [12]; and (iii) IP- Western Blot (WB) on 26 SSc samples with
38-kD antigen band that has a possibility of eIF2B identified by
protein-IP, using a specific anti-eIF2B antibody in 1:500 dilution (Novus
Biological, Colorado, USA) for its confirmation.
2.3. Results
Through the use of the described methods, we identified 3/118 SSc
sera (2.5%) positive for anti-eIF2B antibodies, and the main features of
patients are described in Table 1 and shown in Fig. 1. Similar to reports
from 2016 to 2018 [12,13], two of 3 anti-eIF2B-positive patients with
SSc had a diffuse variant with coexisting ILD, while one had limited SSc
with digital ulcers and Raynaud’s phenomenon. One anti-eIF2B-positive
case had an overlap syndrome of SSc and myositis, with no other serum
autoAb associated, while patient #3 has a history of lung cancer and we
also confirmed by IP positivity of anti-Scl70/topo I and
anti-mitochondrial antibodies in this case. The IIF associated with
anti-eIF2B antibodies was negative for ANA while all 3
anti-eIF2B-positive sera manifested a cytoplasmic staining at titers
exceeding >1:320 (Fig. 1 panel A).
2.4. Discussion
We detected the presence of anti-eIF2B antibodies in 2.5% of SSc sera,
supporting the rarity of this new autoAb described for the first time in
2016 [12]. Our results confirm that it is crucial to use specific laboratory
techniques, namely protein-IP and IP-WB, to identify new and rare
autoAbs such as the anti-eIF2B antibodies (Fig. 1 panels B and C). The
most commonly detected autoAbs associated with SSc (directed against
centromere, Scl70/topoI and RNApolIII) are found in as much as 50–70%
of SSc cases, but the remaining 30–50% have anti-U3RNP/fibrillarin,
anti-Th/To or unknown specificities that cannot be detected by routine
methods and they require additional methods in research settings [5,10,
16]. Through the combination of different testing methods, we could
confirm that anti-eIF2B antibodies are present in different areas and
ethnicity and not only in British SSc patients. This aspect is important
because the prevalence of autoAbs in SSc patients can differ based on
geographic areas, ethnic groups, and gender as demonstrated previously
[2,17].
After confirming the 3 positive anti-eIF2B SSc cases, we analyzed
their clinical and laboratory features as described in Table 1 and we
confirmed the association of anti-eIF2B with diffuse SSc and ILD, and we
did not detect anti-eIF2B antibodies in our control population. The
overlap SSc-myositis was observed in one positive patient, and this is not
surprising based on disease pathogenesis data [12], while another patient
had a diagnosis of lung cancer and the association of anti-eIF2B anti-
bodies with cancer may need further investigation to understand a
possible link with cancer as for anti-RNApolIII [18]. IIF analysis showed a
cytoplasmic staining in all 3 cases, at medium to high titer (Fig. 1 panel
A), which is consistent with the cytoplasmic location of eIF2B, and also
this aspect is concordant with previous reports [12,13]. One of our
anti-eIF2B positive cases also had other autoAbs, namely
anti-Scl70/topoI and anti-mitochondria antibodies as shown in Fig. 1
panel B) [5].
3. AutoAbs associated with ILD in SSc
It is well recognized that the presence of SSc-specific autoAbs confers
a distinctive clinical profile and thus have a prognostic value at the
moment of SSc diagnosis and clinical definition. In the setting of ILD,
specific autoAbs have been reported in association with higher risk for3
this complication (Table 2), in particular anti-Scl70/topoI positivity (p <
0.001) [20–22] more than anti-centromere and anti-RNApolIII anti-
bodies. Additional reports have confirmed that anti-Scl70/topoI autoAbs
are strongly associated with diffuse SSc, ILD (p < 0 0.001), pulmonary
hypertension (PH) (p ¼ 0.019) and ILD with PH (p ¼ 0.003) while
anti-CENPB are associated with limited SSc and inversely with ILD.
Anti-Scl70/topoI have been associated with poor prognosis and higher
mortality rate in severe SSc with ILD [23,24], thus their identification in
the early onset of SSc is important to define specific follow-up exami-
nations such as pulmonary function tests and HRCT. Univariable analysis
revealed that male sex, presence of anti-Scl70/topoI and absence of
anti-centromere were significant predictors of ILD [25]. In a
Cox-regression analysis, a positive anti-centromere [hazard ratio (HR)
0.09 95% confidence interval (95% CI 0.01–0.73)] was confirmed to be a
protective factor [25]. “Normal” FVC and CO diffusion in patients with
SSc, especially those with positive anti-Scl70/topoI, should not obviate
consideration of HRCT for ILD evaluation [26] (see Table 2).
Novel autoAbs have been detected in recent years and they have a
prognostic role for specific clinical features (Table 2), similar to what
observed for anti-eIF2B autoAbs in the British and Italian cohorts [12,
13]. Anti-Th/To autoAbs are associated not only with ILD, but also with
PH and inflammatory muscle disease [32,33]. The difference between
limited SSc with anti-centromere versus anti-Th/To is that
anti-Th/To-positive patients usually develop both ILD and PH. Moreover,
pulmonary involvement is significantly more common in the anti-Th/To
than in anti-centromere-positive patients (74% versus 51%, respectively)
[32]. Anti-CXCR3/4 autoAbs and their corresponding receptors have
been shown to be linked with the severity of SSc-ILD, and autoAb levels
can discriminate patients with stable or decreasing lung function for risk
stratification [27]. AutoAbs to BICD2 (bicaudal D2) also represent a new
biomarker in SSc patients without other specific autoAbs, and data
indicate that their major cross-reactive epitope is associated with
anti-CENP-A but, unlike anti-CENP, single specificity anti-BICD2 anti-
bodies associate with ILD and inflammatory myopathy [28]. Anti-Ku
patients with elevated creatine-kinase at baseline may develop ILD and
a diagnosis of SSc and not myositis [29], mainly, but not exclusively, in
patients with diffuse SSc and with a speckled ANA pattern. Conversely,
the presence of anti-centromere was considered protective against ILD as
already mentioned [30]. Additional autoAbs associated with the risk of
ILD in SSc include anti-RP11 and anti-NOR90, in particular in male pa-
tients [31], while patients with isolated SSc-PH are less likely to have
anti-Scl70/topoI autoAbs and they are more prone to be ACA positive.
Another serum reactivity that is more likely to be associated with SSc
renal crisis and malignancy but less to ILD is the anti-RNApolIII [18,32].
Table 3
AutoAbs associated with ILD in PM/DM, and additional clinical associations.
AutoAb Prevalence (%) Disease association Clinical associations
Aminoacyl tRNA synthetases
Jo-1 15–30 PM, DM Anti-synthetase syndrome
PL-7 <5 PM, DM Anti-synthetase syndrome
PL-12 <5 PM, DM, CADM Anti-synthetase syndrome, ILD
EJ <5 PM, DM Anti-synthetase syndrome
OJ <5 PM, DM Anti-synthetase syndrome, ILD
KS <1 PM, DM ILD
MDA5/CADM140 15–20 CADM/ADM CADM, rapidly progressive ILD, severe skin manifestations
Abbreviations: CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; ILD, interstitial lung disease; PM, polymyositis.
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AutoAbs specific for idiopathic inflammatory myopathy (PM and DM)
have been cumulatively coined “myositis-specific autoantibodies (MSA)”
and are clinically useful biomarkers to help not only for the diagnosis but
also for predicting and monitoring specific clinical manifestations such as
ILD (Table 3) [5,33]. Anti-aminoacyl transfer RNA (tRNA) synthetases
(anti-ARS) are a group of autoAbs that recognize the cytoplasmic amino
acid-charging enzymes called “aminoacyl tRNA synthetases”. So far,
autoAbs to eight of them have been reported, including histidyl (Jo-1),
threonyl (PL-7), alanyl (PL-12), glycyl (EJ), isoleucyl (OJ), asparaginyl
(KS), phenylalanyl (ZO), and tyrosyl (YRS/HA) tRNA synthetases [3]. A
report published in 2014 by Nakashima et al. reported that 10% of pa-
tients with idiopathic ILD had anti-aminoacyl transfer RNA (tRNA) syn-
thetases (anti-ARS) [34], which is consistent with the fact that anti-ARS
have a strong association with ILD and ILD may precede myositis in some
cases. Nevertheless, some patients appear to have idiopathic ILD for years
and may not develop myositis.
Reports on anti-PL-12 and anti-KS suggested that they are common in
ILD without myositis [35–37], as reported also by Kalluri and Colleagues
who analyzed the clinical features of 31 anti-PL-12-positive patients and
reported that this autoAb is strongly associated with ILD (3/31 cases
were idiopathic ILD) but less with myositis and arthritis [38], consistent
with an earlier study [35,37]. Marie et al. analyzed 75 anti-Jo-1-positive
patients and 20 anti-PL-7 (n ¼ 15)/PL-12-positive (n ¼ 5) patients and
reported that the latter had milder muscle involvement, less recurrence
of muscle disease and anti-PL-7/PL-12 was associated with early and
severe ILD and gastrointestinal manifestations [39,40]. Hamaguchi et al.
compared the clinical features of patients with different anti-ARS and
reported that CADM or ILD were more associated with anti-PL-12, and
ILD with anti-KS and anti-OJ antibodies [41]. In summary, patients with
antibodies to non-Jo-1 ARS are associated with earlier and more severe
ILD compared with anti-Jo-1 (þ) patients, and they are more likely to
have ILD without typical myositis [3].
Besides ARS, another autoAb associated with ILD is anti-MDA5/
CADM140 which has been reported in association with rapidly pro-
gressive ILD resistant to treatment and with poor prognosis (Table 3)
[42–44]. In a study published by Hall et al. [45], 6.9% (11/160) of DM
had anti-MDA5/CADM140 but 6/11 had overt clinical myopathy and
8/11 had ILD. This cohort of anti-MDA5/CADM140 patients was similar
to anti-synthetase syndrome and they were not associated with RPILD, in
contrast to Asian studies. Another study from Spain reported 12%
(14/117, 8 were CADM) prevalence of anti-MDA5/CADM140 in 117 DM
patients [46].
Eight of 14 anti-MDA5/CADM140-positive patients had RPILD,
similar to Asian cohorts [47] but different from US cohorts [45].
5. Conclusions
Research techniques are fundamental for the identification of new
and rare autoAbs in SSc, as demonstrated by the recent description of
anti-eIF2B antibodies. The data confirm the association of this autoAb
with SSc, and it helps understanding the future possible disease4
development for a better clinical and therapeutic management, as re-
ported previously for other SSc autoAbs [19]. Anti-eIF2B is the autoAb
specificity that should be suspected when SSc patients are negative for
anti-centromere, -Scl70/topoI, -RNApolIII antibodies but have positive
cytoplasmic staining with negative ANA at IIF. Increasing the number of
anti-eIF2B positive patients and understanding their significance in the
SSc disease is of great importance to better manage patients and to allow
the use of this specificity in routine autoimmunity laboratories
worldwide.
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